1 2	THE IMPACT OF COVID-19 ON PATIENTS WITH ASTHMA: A BIG DATA ANALYSIS.
3	
4	
5	José Luis Izquierdo <sup>(1,2)</sup> , Carlos Almonacid <sup>(2,3),</sup> Yolanda González <sup>(4)</sup> , Carlos Del
6 7	Rio-Bermúdez <sup>(4)</sup> , Julio Ancochea <sup>(5,6,7)</sup> , Remedios Cárdenas <sup>(8)</sup> , and Joan B Soriano <sup>(5,6,7)</sup>
/	Sonano
8	
9	<sup>1</sup> Respiratory Medicine. University Hospital of Guadalajara, Guadalajara
10	<sup>2</sup> Department of Medicine and Medical Specialties. University of Alcalá, Madrid
11	<sup>3</sup> Respiratory Medicine. University Hospital Ramón y Cajal, Madrid
12	<sup>4</sup> Savana Medica
13	<sup>5</sup> Respiratory Medicine. Hospital Universitario de La Princesa, Madrid
14	<sup>6</sup> Universidad Autónoma de Madrid. Madrid
15 16	<sup>7</sup> Respiratory Diseases Networking Biomedical Research Centre (CIBERES). Institute of Health Carlos III (ISCIII), Madrid
17	<sup>8</sup> Allergy. University Hospital of Guadalajara, Guadalajara
18	All in Spain
19	
20	Address for correspondence:
21	Dr. Joan B Soriano
22	Servicio de Neumología
23	Hospital Universitario de la Princesa-UAM
24	Diego de León 62, 28005-Madrid, Spain
25	Email: jbsoriano2@gmail.com
26	Cellular: +34 618867769
27	
28	Funding. Grant COVID-19 UAH 2019/00003/016/001/005 from the University of Alcalá

29 (Spain).

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 30 ABSTRACT

Background: From the onset of the COVID-19 pandemic, an association between the
severity of COVID-19 and the presence of certain medical chronic conditions has been
suggested. However, unlike influenza and other viruses, the burden of the disease in
patients with asthma has been less evident.

Objective: This study aims at a better understanding of the burden of COVID-19 in
 patients with asthma and the impact of asthma, its related comorbidities, and treatment
 on the prognosis of COVID-19.

Methods: We analyzed clinical data from patients with asthma from January 1<sup>st</sup> to May
 10<sup>th</sup>, 2020 using big data analytics and artificial intelligence through the SAVANA
 Manager<sup>®</sup> clinical platform.

41 **Results**: Out of 71,192 patients with asthma, 1,006 (1.41%) suffered from COVID-19. 42 Compared to asthmatic individuals without COVID-19, patients with asthma and COVID-43 19 were significantly older (55 vs. 42 years), predominantly female (66% vs. 59%), had higher prevalence of hypertension, dyslipidemias, diabetes, and obesity, and smoked 44 more frequently. Contrarily, allergy-related factors such as rhinitis and eczema were less 45 frequent in asthmatic patients with COVID-19 (P < .001). Higher prevalence of 46 hypertension, dyslipidemia, diabetes, and obesity was also confirmed in those patients 47 with asthma and COVID-19 who required hospital admission. The percentage of 48 individuals using inhaled corticosteroids (ICS) was lower in patients who required 49 hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% vs. 50 61.5%; OR: 0.58: 95% CI 0.44 - 0.77). During the study period, 865 (1.21%) patients with 51 asthma were being treated with biologics. Although these patients showed increased 52 severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital 53 admission rates due to COVID-19 were relatively low (0.23%). COVID-19 increased 54 inpatient mortality in asthmatic patients (2.29% vs 0.54%; OR 2.29: 95% CI 4.35 - 6.66). 55

56 Conclusion: Our results indicate that the number of COVID-19 cases in patients with 57 asthma has been low, although higher than the observed in the general population. 58 Patients with asthma and COVID-19 were older and were at increased risk due to 59 comorbidity-related factors. ICS and biologics are generally safe and may be associated 60 with a protective effect against severe COVID-19 infection.

#### 61 INTRODUCTION

Asthma remains a global major challenge for public health. Affecting approximately 272 62 63 million people of all ages (4.5% of adults aged 18-50), asthma is one of the most common 64 chronic disorders worldwide (1,2). In the United States, it has been estimated that up to 12 million people experience an acute exacerbation of their asthma ever year, a quarter 65 of which require hospitalization (3). In Europe, asthma ranks 14<sup>th</sup> in terms of duration and 66 67 associated disability, and leads to an estimated cost of EUR 25 billion per year (4). In Spain, 5% of adults and 10% of children have asthma. However, up to 50% of patients 68 remain undiagnosed. Indeed, 8.6% of adults (aged 18-70) and 14% of children show 69 70 asthma-related symptoms, being dyspnea and cough the most common (4,5). Yet, 71 between 60% and 70% of patients with asthma in Spain are not properly controlled (6, 72 7). This is critical since patients with uncontrolled asthma may generate ten times as much direct and indirect costs than controlled patients (1). 73

The severity of the disease is related to uncontrolled bronchial asthma in many patients; in other cases, worsening symptoms and asthma exacerbation are associated with treatment-related variables (e.g., inappropriate treatment, lack of adherence) or with the presence of underlying risk factors (6-8), most notably viral respiratory infection. Asthma exacerbations caused by respiratory infections or other conditions have a negative impact on the patient's health status and lead to worse prognosis.

COVID-19 is the disease caused by the severe acute respiratory syndrome 80 81 coronavirus 2 (SARS-CoV-2). Clinically, the severity of COVID-19 can vary from mild to very severe, causing mortality in some patients (9,10). The ongoing COVID-19 pandemic 82 certainly represents a major challenge for health systems globally. Since the beginning 83 of the pandemic, an association between COVID-19 severity and chronic medical 84 conditions such as cardiovascular disease, diabetes mellitus, and high blood pressure 85 has been suggested. Unlike influenza and other seasonal viruses however, the impact 86 of COVID-19 in patients with asthma has been less evident (11-14). On the other hand, 87

88 the severity and mortality of COVID-19 has been strongly related with age. Although the 89 virus can infect individuals of all ages, most severe cases to date have been described 90 in adults 55 years and older, and in patients with the aforementioned comorbidities. In 91 this age group, patients typically have more than one chronic condition, particularly endocrine-metabolic and cardiovascular diseases. With this background, it is imperative 92 93 to characterize the clinical course of SARS-CoV-2 infection in patients with asthma and assess the impact of asthma and asthma-related comorbidities and treatment in COVID-94 95 19-related outcomes.

Emerging and rapidly evolving diseases such as COVID-19 are best understood using population-based registries containing real-world information (15). In this context, combining real-world data with big data analytics has the potential to increase our understanding of the effects of COVID-19 in patients with asthma and identify new strategies and management options for therapeutic intervention. A relevant data source with the above-mentioned characteristics is the clinical information contained in patients' electronic health records (EHR).

Using the clinical information captured in the EHRs of patients with asthma and COVID-19, here we aimed to *a*) describe the frequency and clinical characteristics of these patients and *b*) understand the clinical impact of COVID-19 on the clinical course of patients with asthma. To achieve the study objectives, we used big data analytics and artificial intelligence (AI) through the SAVANA *Manager*<sup>®</sup> clinical platform (16-17).

108

#### 109 METHODS

This was a multi-center, non-interventional, retrospective study using free-text data
captured in the EHRs of patients diagnosed of COVID-19. The study period was January
1, 2019 - May 10, 2020.

We followed the Strengthening the Reporting of Observational Studies in 113 Epidemiology (STROBE) guidelines for reporting observational studies (18). The study 114 115 was conducted in accordance with legal and regulatory requirements and followed 116 research practices described in the ICH Guidelines for Good Clinical Practice, the 117 edition, Declaration of Helsinki in its latest the Guidelines for Good Pharmacoepidemiology Practice (GPP), and local regulations. Given the retrospective 118 and observational nature of the study, physicians' prescribing habits and patient 119 120 assignment to a specific therapeutic strategy were solely determined by the physician, 121 team, or hospital concerned. Likewise, a standard informed consent does not apply to 122 this study. All actions towards data protection were taken in accordance with the European Data Protection authorities' code of good practice regarding big data projects 123 124 and the European General Data Protection Regulation (GDPR). This study was 125 approved by the Ethics and Research Committee of the University Hospital of 126 Guadalajara (Spain).

127 Clinical data from a total of 2,034,921 patients with available EHRs in the region 128 of Castilla La-Mancha (Spain) were explored. Data were collected from all available 129 services, including inpatient and outpatient departments, emergency room, and primary 130 care.

The information from EHRs was extracted with Natural Language Processing 131 132 (NLP) and AI techniques using SAVANA Manager<sup>®</sup>, a powerful multilingual (natural 133 language) engine for the analysis of free-text clinical information. This software is able 134 to interpret any content included in electronic clinical records, regardless of the electronic 135 system in which it operates. Importantly, this tool can capture numerical values and 136 clinical notes and transform them into accessible variables, thus allowing for the reuse 137 of the information captured in large-scale collections of clinical records (i.e., big data). 138 The data extraction process has four distinct phases aimed at transferring and aggregating the data into the study database, namely a) Acquisition: data acquisition is 139

the responsibility of the participating site, in close collaboration with SAVANA's 140 Information Technology staff. In compliance with the EU GDPR, data were anonymized 141 142 and transferred to SAVANA during this phase; b) Integration: In this phase, data were integrated into the database; c) NLP processing: SAVANA's EHRead® technology 143 144 applied NLP techniques to analyze and extract the unstructured free-text information written in large amounts of EHRs. The NLP output is a synthetic patient database, as the 145 software creates a patient database from scratch. This process ensures that this 146 147 information is inaccessible and makes traceability to individual patients impossible; and d) Validation, consisting of a medical validation of the tool's output by doctors and 148 researchers. 149

150 The terminology used by SAVANA is based on multiple sources such as 151 SNOMED CT (19), which includes medical codes, concepts, synonyms, and definitions 152 regarding symptoms, diagnoses, body structures, and substances commonly used in 153 clinical documentation. Due to the novel methodological approach of this study, we complemented our clinical findings with the assessment of EHRead's performance. This 154 155 evaluation was aimed at verifying the system's accuracy in identifying records that 156 contain mentions of asthma and COVID-19 and its related variables. For a comprehensive description of the evaluation procedure, see (19). Briefly, the annotations 157 made by the medical experts were used to generate the gold standard to assess the 158 159 performance of EHRead's output; performance is calculated in terms of the standard 160 metrics of accuracy (P), recall (R), and their harmonic mean F-score (20).

All statistical analyses were conducted using SPSS software (V25.0). Unless otherwise indicated, qualitative variables are expressed as absolute frequencies and percentages, while quantitative variables are expressed as means and standard deviations. For the assessment of statistical significance of numerical variables, we used independent samples Student's T-tests or ANOVA. To measure the relative distribution

166 of patients assigned to different categories of qualitative variables, we used Chi<sup>2</sup> tests.

167 In all cases, a p value for statistical significance was set at 0.05.

168

## 169 **RESULTS**

We identified 71,192 patients with asthma during the study period (January 1, 2019 -May 10, 2020). The search terms used to identify patients with bronchial asthma are listed in **eTable 1**. For the linguistic evaluation of the variable 'asthma', we obtained Precision, Recall, and F- Scores of 0.88, 0.75, and 0.81, respectively; these metrics indicate that patients with asthma were properly identified within the target population. The patient flowchart for asthmatics with and without COVID-19 is depicted in **Figure 1**.

176 Patients' age (mean  $\pm$  SD) was 42  $\pm$  20 years; 59% of patients were women. 177 Overall, 1,006 (1.41%) asthma patients were also diagnosed with COVID-19. EHRead 178 identified COVID-19 with a Precision of 0,99, a Recall of 0,75, and a F-Score of 0,93; 179 again, these results indicate that within our population with asthma, COVID-19 cases were accurately identified. COVID-19 diagnosis was confirmed by PCR in 61% of 180 patients (n = 611); in the remaining cases, and considering the epidemiological context 181 of the pandemic in the study area between March and May 2020, diagnosis was based 182 on rapid serological tests or clinical, radiological, and/or analytical evaluation, Notably, 183 184 the percentage (95% CI) of patients diagnosed with COVID-19 in the population of patients with asthma (1.41%; 1.33 – 1.50) was significantly higher than in the general 185 population of Castilla La-Mancha (Spain) (0.86%; 0.85 - 0.87), P <.001. 186

Patients with asthma who also had a diagnosis of COVID-19 were older, predominantly women, and had higher prevalence rates of hypertension, dyslipidemia, diabetes, obesity, and smoking habits than asthmatic individuals without COVID-19 (all P < .05). By contrast, atopy-related factors such as rhinitis or eczema were significantly more frequent in patients without COVID-19 (**Table 1**). The higher prevalence of

hypertension, dyslipidemia, diabetes, and obesity was further confirmed in those patients
requiring hospital admission, as compared with those who only required outpatient
management (**Table 2**).

The proportion of patients with asthma using inhaled corticosteroids (ICS) was significantly lower in individuals requiring hospital admission (48.3% vs 61.5%) respectively, with an OR (95% Cl) of 0.58 (0.44 - 0.77). The most common diagnosis in hospitalized patients was pneumonia (91% of patients; n = 239), with great variability of radiological expression. Different diagnoses associated with respiratory failure but with normal lung radiology (data not shown) were found in 9% (n = 24) of patients.

201 Regardless of previous ICS or bronchodilator use, a total of 865 patients in the 202 study population were being treated with biologics during the study period, due to 203 previous poor control of the disease (**Table 3**). Biologics-treated patients showed a high 204 frequency of rhinitis and polyposis (50% in both cases), and a greater number of 205 bronchospasm episodes before treatment onset with biologics. Despite increased 206 severity and comorbidity of symptoms at the ear, nose, and throat (ENT) level, the need 207 for COVID-19-related hospital admission in biologics-treated patients with asthma was relatively marginal (0.23%; 0.03 - 0.83). This proportion markedly differs from the 208 209 observed in both the general population and in the population of patients with asthma 210 not being treated with biologics; in both cases 26% of patients required hospitalization 211 due to COVID-19. Only one patient undergoing treatment with biologics died; he was a 52-year-old male with high blood pressure, diabetes mellitus, and dyslipidemia. 212

Compared with information from patients with asthma available since January 2019, the data collected during the study period (January 1<sup>st</sup> to May 10<sup>th</sup>, 2020) show that COVID-19 significantly increased in-hospital mortality in this population (0.54% vs 2.29%), with an associated OR (95% CI) of 4.35 (2.84 - 6.66). For both periods, inhospital mortality mainly affected elderly patients, with an average age ( $\pm$ SD) of 76 ( $\pm$ 12) years in patients with both asthma and COVID-19, and 78 ( $\pm$ 17) in COVID-19-free

patients with asthma, P < .001); most of these patients were women in both study periods (61% and 71%, respectively, and had previously diagnosed comorbidities (**Table 4**). On the other hand, the age distribution (mean ± SD) of patients without asthma who died from COVID-19 was 79 ± 11 years, and 63% (n = 296) of them were male.

223

#### 224 DISCUSSION

The WHO declared the COVID-19 outbreak a global pandemic on March 11, 2020. Ever since, clinicians worldwide have been particularly concerned about the impact of patients' preexisting chronic conditions (particularly lung and cardiovascular diseases) on the course of this new disease. Whereas high blood pressure and diabetes have been closely associated with increased frequency of cases and severity of COVID-19, carerelated data suggest that COVID-19 has not affected patients with asthma to nearly the same extent (13,21-23).

232 To shed light on this question, we have applied big data analytics and AI to 233 analyze the clinical information of a large cohort of patients with asthma and COVID-19. Big data applications in healthcare (specifically the use of new technologies to manage 234 and extract the complex data generated in large volumes of EHRs) is an inescapable 235 236 reality (24). Crucially, most of the information contained in EHRs is found in an 237 unstructured form (e.g., as free-text narratives or clinical notes). The use of big data 238 analytics and cutting-edge methods in the realm of AI (i.e., NLP, machine learning) now 239 allows for the extraction and analysis of this valuable information in real time. The 240 software use in the present study enable the rapid evaluation of the main indicators of various clinical processes while avoiding the selection biases that occur in audit or case 241 series studies, where only specialized centers and medical professionals participate in 242 243 the study. Importantly, the Spanish Autonomous Community of Castilla-La Mancha has 244 different features that optimize the use of this technology to analyze the clinical impact 245 of COVID-19 on patients with asthma. First, this region has been one of the most affected

by the pandemic in Spain, which in turn has been one of the most hard-hit countries in Europe. Second, it has a good EHR system, which has been standardized and is shared across all five provinces. Finally, the SAVANA *Manager*<sup>®</sup> tool is widely available in the region, allowing access to large amounts of clinical information (25).

In the present study, we analyzed clinical data from the largest population of asthma patients published to date (n = 71,192); 1,006 of these patients were diagnosed with COVID-19. The study period was January 1, 2019-May 10, 2020. Although the system allows us to analyze data from 2011 onwards, we selected this temporal cut-off to include asthmatic patients with updated follow-up information and with the active form of the disease.

256 The proportion of patients with both asthma and COVID-19 during the study 257 period was 1.41%, which is markedly higher than the 0.86% observed in the general 258 population. Although these data show a higher frequency of COVID-19 in patients with 259 asthma, the manifestation of the disease in this clinical population was not particularly 260 severe, with low rate of hospital admissions. In addition, this proportion is lower than the reported for patients with other chronic diseases. Some of the reasons that may explain 261 this phenomenon include remission of seasonal influenza, lack of exposure to 262 263 environmental factors, greater monitoring of hygiene measures during lockdown in these patients, the significant reduction in air pollution during this period, and/or better control 264 265 of the disease by improving adherence to treatment due to fear of worsening 266 symptomatology. This trend was already observed since the initial phases of the pandemic in patient populations with other respiratory diseases such as COPD (26). 267

Comorbidities play a major role in the manifestation of COVID-19-related complications. In our study, the manifestation of COVID-19 in patients with asthma was favored by older age, male sex, and the presence of several comorbidities. High blood pressure, dyslipidemia, diabetes, and obesity were the main risk factors for hospital admission due to poor prognosis. The lower risk associated with rhinitis and eczema is

consistent with previous observations that allergic sensitization in asthma is linked to
lower expression of ACE2 receptors in both upper and lower respiratory airways,
suggesting a potential protective effect (27). As previously observed in the general
population, mortality due to COVID-19 in patients with asthma mainly occurred in the
elderly.

278 The possibility that different therapeutic options in patients with chronic 279 respiratory diseases affects the incidence and prognosis of COVID-19 has been a matter 280 of intense debate. As for asthma, it has been suggested that the use of ICS might yield a protective effect against COVID-19 (28,29). Although an antiviral effect has been 281 282 described in rhinovirus-induced exacerbations, these results are highly controversial. Peters et al (30) showed an association of ICS use and reduced expression of both ACE2 283 284 and TMPRSS2 receptors, thus implying that ICS may reduce the risk for SARS-CoV-2 285 infection and decrease COVID-19-related morbidity. Although our data cannot answer 286 this question in a conclusive manner, they show that the proportion of patients who used 287 ICS was significantly reduced in asthmatics who required hospitalization due to COVID-288 19. These findings are consistent with other studies showing that a combination of 289 glycopyronium, formoterol, and budesonide prevents the replication of HCoV-229E (via 290 inhibition of receptor expression and/or endosomal function), and that these drugs 291 modulate infection-related inflammation in the respiratory tract (31). In our study, the 292 three cortico-dependent patients in our study diagnosed with COVID-19 did not die from 293 it; however, there is no experimental evidence to date regarding the effect of systemic 294 corticosteroids in patients with asthma and COVID-19.

Whether treatment with biologics in patients with asthma impacts SARS-CoV-2 infection or the incidence and prognosis of COVID-19 also remains unknown. In this context, there is no evidence supporting that either omalizumab or other drugs that suppress eosinophils directly modulate viral processes in patients with asthma (32,33). In our study, we identified a total of 865 patients treated with biologics. Among these,

two patients required admission and only one died from COVID-19; this patient, however, had other comorbidities in addition to severe asthma, which may have contributed to his poor clinical outcome. Overall, our results support the safety of these drugs for the treatment of asthma in patients diagnosed with COVID-19. As with ICS use, our data suggest that biologics might be associated with a protective effect on the clinical course of these patients. However, we cannot rule out that the aforementioned favorable factors also contributed to a better disease prognosis.

307 Our findings are consistent with a recently reported clinical series of 220 asthmatic patients with COVID-19 in Chicago and surrounding Illinois suburbs, where 308 309 asthma was not associated with an increased risk of hospitalization after adjusting for age, sex, gender, and comorbidities (RR of 0.96 [95%CI: 0.77-1.19]) (34). However, ICS 310 use was associated with a non-statistically significant increased risk of hospitalization 311 312 (RR of 1.39 [95%CI: 0.90-2.15]); in the same report, however, the interpretation of the 313 effects of combined use of ICS and long-acting beta agonists (LABA) and levels of care in these patients was not straightforward. These results warrant further research in 314 315 patients with asthma and other clinical populations.

316

#### 317 Strengths and Limitations

318 The strengths of the present study include immediacy, large sample size, and real-world evidence. In addition, our results must be interpreted in light of the following limitations. 319 320 Frist, the main limitation of this type of studies is perhaps the lack of documented 321 information. In Castilla-La Mancha, the digitalization of clinical records has been optimal 322 since 2011. Not only the EHRs system is homogenous throughout the region, but its use 323 has been universal for the past five years. Second, unlike classical research methods, 324 reproducibility is not generally considered in big data studies, since the latter involve 325 large amounts of information collected from the whole target population. Because we

exclusively analyzed the data captured in EHRs, the quality of the results reported for 326 327 some variables is directly tied to the quality of the clinical records; in many cases, EHRs 328 may be partially incomplete and not capture all the relevant clinical information from a 329 given patient. Third, because this study was not designed to collect variables in a strict, 330 a priori fashion, there were some variables that were not properly documented and were 331 therefore not analyzed. Finally, our study sample comprised COVID-19 cases confirmed 332 by both PCR/serological tests and clinical criteria (i.e. symptomatology, imaging, and 333 laboratory results). Of note, PCR and other rapid laboratory tests for the detection of 334 SARS-CoV-2 were not routinely used in Spain during the onset of the pandemic. The decision to include clinically diagnosed COVID-19 cases is further supported by recent 335 data questioning the clinical validity and sensitivity of symptom- and image-based 336 identification of patients with COVID-19, especially in the early stages of the disease (35-337 338 37).

339

#### 340 Conclusion

We conclude that a) the frequency of SARS-CoV-2 infection has been low in patients 341 342 with asthma, although higher than in the general population, b) the increased risk for hospitalization due to COVID-19 in patients with asthma is largely associated with age 343 344 and related comorbidities; mortality mainly affected elderly patients, c) ICS showed a 345 safe profile; compared to asthmatic patients who required hospitalization due to COVID-346 19, a significantly higher percentage of non-hospitalized patients used ICS, and d) although biologics-treated patients with asthma typically present with the most severe 347 348 manifestations of the disease, the number of COVID-19-related admissions and mortality 349 in these patients was strikingly low, thus suggesting a protective effect associated with 350 the use of these therapeutic agents.

351

## 352 **REFERENCES**

353

354	1.	The Global Asthma Report 2014. Available at: http://
355		www.globalasthmareport.org/ burden/ burden.php
356	2.	GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable
357		health burden of chronic respiratory diseases, 1990-2017: a systematic analysis
358		for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020 Jun; 8
359		(6):585-596. doi: 10.1016/S2213-2600(20)30105-3.
360	3.	Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. J
361		Allergy Clin Immunol. 2017; 139 (2): 438-447. doi: 10.1016/j.jaci.2016.06.054.
362		Epub 2016 Aug 20. Review.
363	4.	Gibson GJ, Loddenkemper R, Lundbäck B, Sibille Y. Respiratory health and
364		disease in Europe: the new European Lung White Book. Eur Respir J. 2013; 42
365		(3):559–63.
366	5.	Urrutia I, Aguirre U, Sunyer J, Plana E, Muniozguren N, Martínez-Moratalla J, et
367		al. Cambios en la prevalencia de asma en la población española del Estudio de
368		Salud Respiratoria de la Comunidad Europea (ECRHSII). Arch Bronconeumol.
369		2007; 43(8):425-30.
370	6.	Quirce S, Plaza V, Picado C, Vennera M, Casafont J. Prevalence of uncontrolled
371		severe persistent asthma in pneumology and allergy hospital units in Spain. J
372		Investig Allergol Clin Immunol 2011; 21: 466–71.
373	7.	Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM, Molina J, et al.
374		Measurement of asthma control according to Global Initiative for Asthma
375		guidelines: a comparison with the Asthma Control Questionnaire. Respir Res
376		2012; 13:50. https://doi.org/10.1186/1465-9921-13-50.
377	8.	Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. The Lancet 2018; 391:
378		783–800. https://doi.org/10.1016/S0140-6736 (17) 33311-1
379	9.	World Health Organization. Coronavirus disease (COVID-19) outbreak
380		https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-
381		they-happen.
382	10	D. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission
383		Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. New
384		England Journal of Medicine. 2020 Mar 26;382(13):1199-1207. doi:
385		10.1056/NEJMoa2001316.

- 11. Chow EJ, Doyle JD, Uyeki TM. Influenza virus-related critical illness: prevention,
  diagnosis, treatment. Crit Care. 2019 Jun 12;23(1):214. doi: 10.1186/s13054019-2491-9.
- 389 12. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical
  390 Characteristics of Covid-19 in New York City. N Engl J Med 2020.
  391 https://doi.org/10.1056/NEJMc2010419.
- 13. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and
  mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020.
  https://doi.org/10.1016/j.jaci.2020.04.006.
- 395 14. Johnston SL. Asthma and COVID-19: is asthma a risk factor for severe
  396 outcomes? Allergy 2020. https://doi.org/10.1111/all.14348.
- 397 15. Mallappallil M, Sabu J, Gruessner A, Salifu M. A review of big data and medical
  398 research. SAGE Open Med. 2020 Jun 25; 8: 2050312120934839. doi:
  399 10.1177/2050312120934839. eCollection 2020
- 400 16. Hernandez Medrano ITG, J; Belda, C; Urena, A; Salcedo, I; Espinosa-Anke, L;
  401 Saggion, H. SAVANA: Re-using Electronic Health Records with Artificial
  402 Intelligence. International Journal of Interactive Multimedia and Artificial
  403 Intelligence. 2017; 4 (7):8-12.
- 404 17. Espinosa-Anke LT, Pardo A, Medrano I, Ureña A, Salcedo I, Saggion H.
  405 SAVANA: A Global Information Extraction and Terminology Expansion
  406 Framework in the Medical Domain Procesamiento del Lenguaje Natural.
  407 2016; 57: 23-30.
- 408 18. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP;
  409 STROBE Initiative. The Strengthening the Reporting of Observational Studies in
  410 Epidemiology (STROBE) statement: guidelines for reporting observational
  411 studies. Lancet 2007; 370: 1453-1457.
- 412 19. Benson T. Principles of Health Interoperability HL7 and SNOMED. London:
  413 Springer. 201.
- 20. Baeza-Yates RA, Ribeiro-Neto B. 1999. Modern Information Retrieval. AddisonWesley Longman Publishing Co., Inc., Boston, MA, USA.
- 21. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical
  characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China.
  Allergy 2020. https://doi.org/10.1111/all.14238.
- 22. Liu S, Zhi Y, Ying S. COVID-19 and Asthma: Reflection During the Pandemic.
  Clin Rev Allergy Immunol 2020. https://doi.org/10.1007/s12016-020-08797-3.


421 23. Gupta A, Bush A, Nagakumar P. Asthma in children during the COVID-19
422 pandemic: lessons from lockdown and future directions for management. Lancet
423 Respir Med 2020 Published Online June 25, 2020.
424 https://doi.org/10.1016/S2213-2600(20)30278-2

- 425 24. Almonacid Sánchez C, Melero Moreno C, Quirce Gancedo S, Sánchez-Herrero MG, Álvarez Gutiérrez FJ, Bañas Conejero D, et al. PAGE Study: Summary of a 426 427 study protocol to estimate the prevalence of severe asthma in Spain using bigdata methods. J Investia Allergol Clin Immunol 2020:0. 428 429 https://doi.org/10.18176/jiaci.0483.
- 25. Izquierdo JL, Morena D, Gonzalez Y, Paredero JM, Perez B, Graziani D,
  Gutierrez M, Rodriguez JM. Clinical Management of COPD in a Real-World
  Setting. A Big Data Analysis. Arch Bronconeumol 2020. 2020 Feb 22; S03002896(20)30012-0. doi: 10.1016/j.arbres.2019.12.025.Online ahead of print
- 434 26. Guan W-J, Liang W-H, Zhao Y, et al on behalf of China Medical Treatment Expert
  435 Group for COVID-19. Comorbidity and its impact on 1590 patients with COVID436 19 in China: a nationwide analysis. Eur Respir J. 2020; In press. doi:
  437 https://doi.org/10.1183/13993003.00547-2020.
- 438 27. Wang R, Bikov A, Fowler SJ. Thorax Epub ahead of print. doi:10.1136/thoraxjnl439 2020-2151189.
- 28. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a
  systematic review and clinical perspective. Eur Respir J 2020;55.
  https://doi.org/10.1183/13993003.01009-2020
- 443 29. Grünberg K, Sharon RF, Sont JK, et al. Rhinovirus-Induced airway inflammation
  444 in asthma: effect of treatment with inhaled corticosteroids before and during
  445 experimental infection. Am J Respir Crit Care Med 2001; 164: 1816–22.
- 30. Peters MC, Sajuthi S, Deford P, Christenson S, Rios CL, Montgomery MT, et al;
  National Heart, Lung, and Blood Institute Severe Asthma Research Program-3
  Investigators. COVID-19 Related Genes in Sputum Cells in Asthma: Relationship
  to Demographic Features and Corticosteroids. Am J Respir Crit Care Med. 2020
  Apr 29. doi: 10.1164/rccm.202003-0821OC. Online ahead of print.
- 451 31. Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K, et al.
  452 Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus
  453 HCoV-229E replication and cytokine production by primary cultures of human
  454 nasal and tracheal epithelial cells. Respir Investig. 2020 May;58(3):155-168. doi:
  455 10.1016/j.resinv.2019.12.005. Epub 2020 Feb 21.

- 456 32. Esquivel A, Busse WW, Calatroni A, et al. Effects of omalizumab on rhinovirus
  457 infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med
  458 2017; 196: 985–92
- 33. Sabogal Piñeros YS, Bal SM, van de Pol MA, et al. Anti-IL-5 in mild asthma alters
  rhinovirus-induced macrophage, B-cell,and neutrophil responses (material). A
  placebo-controlled, double-blind study. Am J Respir Crit Care Med 2019; 199:
  508–17.
- 34. Chhiba KD, Patel GB, Vu THT, et al. Prevalence and characterization of asthma
  in hospitalized and non-hospitalized patients with COVID-19 [published online
  ahead of print, 2020 Jun 15]. *J Allergy Clin Immunol*. 2020; S00916749(20)30840-X. doi: 10.1016/j.jaci.2020.06.010
- 35. Long C, Xu H, Shen Q, Zhang X, Fan B, Wang C, Zeng B, Li Z, Li X, Li H.
  Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Eur J Radiol
  2020: 126: 108961.
- 36. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, Tan W. Detection of SARS-CoV-2 in
  Different Types of Clinical Specimens. JAMA 2020.
- 37. T, Yang Z, Hou H, Zhan 429 C, Chen C, Lv W, Tao Q, Sun Z, Xia L. Correlation
  of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in
  China: A Report of 1014 Cases. Radiology: 0(0): 200642.

#### 475 **FIGURES**

#### 476



477

FIGURE 1. Patient Flowchart. Flowchart depicting the total number (%) of patients with available EHRs, the number of patients with asthma, the number of patients diagnosed with COVID-19, and of those, the number of hospitalizations after diagnosis during the study period (January 1<sup>st</sup>, 2020-May 10<sup>th</sup>, 2020). All percent values are computed in relation to the immediately above level.

# 483 **TABLES**

# Table 1. Demographic and clinical characteristics of patients with asthma with/without COVID-19

486

	Asthma (n=71,192)	Asthma without COVID-19	Asthma with COVID-19	OR (95% CI)
	(11-11,102)	(n=70,544)	(n=1,006)	P value *
Age				
Years (mean ± SD)	42 <u>+</u> 24	41 <u>+</u> 24	55 <u>+</u> 20	< .001
Sex				
Female (%)	59	58	66	1.35 (1.18 – 1.54) <.001
Tobacco use (%)	10	9	11	1.25 (1,03 -1.53) 0.02
Comorbidities				
Arterial Hypertension (%)	24	23	39	2.02 (1.78 - 2.30) <.001
Dyslipidemia (%)	17	16	26	1.85 (1.60 – 2.13) <.001
Diabetes Mellitus (%)	11	11	16	1.54 (1.30 – 1.82) <.001
Obesity (%)	10	9	13	1.35 (1.12-1.62) <.001
Rhinitis (%)	33	33	17	0.42 (0.35 -0.49) <.001
Eczema (%)	7	7	1	0.50 (0.40 – 0.76) <.001

\* Patients with asthma with COVID-19 vs. patients with asthma without COVID-19

# Table 2. Demographic and clinical characteristics of patients with asthma and COVID-19 that required a hospital admission.

490

	Asthma + COVID-19 (n=1,006)	Asthma + COVID-19 Non-Hospitalized (n=743)	Asthma + COVID-19 Hospitalized (n=263)	OR (95% CI) <i>P</i> value *
Age				
Years (mean ± SD)	55 <u>+</u> 20	52 <u>+</u> 20	63 <u>+</u> 18	<.001
Sex				
Female (%)	66	67	61	0.76 (0.57 – 1.02) 0.07
Tobacco use (%)	7	7	6	0.69 (0.37 – 1.29) 0.29
Comorbidities				
Arterial Hypertension (%)	39	34	54	2.27 (1.71 – 3.03) <.001
Dyslipidemia (%)	27	21	38	2.31 (1.70 – 3.13) <.001
Diabetes Mellitus (%)	15	13	21	1.76 (1,22 – 2,54) 0.002
Obesity (%)	13	12	18	1.60 (1.09 – 2.35) 0.02

\* Non-hospitalized patients vs. hospitalized patients

	Asthma + COVID-19	Asthma + COVID-19 Hospitalized	<i>P</i> value
	(Jan. 1 <sup>st</sup> - May 10 <sup>th</sup> , 2020)	(Jan 1 <sup>st</sup> -May 10th, 2020)	
Patients with asthma (N = 71.192) (Jan 1 <sup>st</sup> , 2019 – May 10 <sup>th,</sup> 2020)	1.006	263	
Asthma + $\geq$ 1 ICS (N = 42.171; 59,23% of asthmatics)	619	127	<.001
Asthma + $\geq$ 1 Biologics (N = 865; 1,21% of asthmatics) *	18	2	
Omalizumab (n=641)	9	0	
Mepolizumab (n=308)	7	2	
Benralizumab (n=98)	2	0	
Reslizumab (n=26)	1	0	

# Table 3. Treatment of patients with asthma and COVID-19: ICS and biologics in hospitalized vs. non-hospitalized patients.

\* 54% of the patients treated with Mepolizumab had been previously treated with Omalizumab; 65% of patients treated with Benralizumab had previously been treated with Omalizumab and 35% with Mepolizumab. Most of the patients treated with Reslizumab had been previously treated with Omalizumab and Mepolizumab.

### 495 Table 4. In-hospital mortality in asthmatic patients with / without COVID-19

496

	Asthma with COVID-19	Asthma without COVID-19	OR (95% CI) <i>P</i> value
Age			
Years (mean ± SD)	78 <u>+</u> 17	76 <u>+</u> 17	<.001
Sex			
Female (%)	61	71	0.64 (0.56 – 0.73)
Mortality (%)	2.29	0.54	2.29 (4.35 – 6.66)

497

## 499**ONLINE APPENDIX**

500

#### 501 eTable 1. Search terms used to identify patients with bronchial asthma

- Unstable asthma
- Adult-onset asthma
- Intrinsic asthma
- Asthma attack / Asthma exacerbation
- Acute asthma
- Exercise-induced asthma
- Childhood asthma
- Asthmatic bronchitis
- Cough-variant asthma
- Allergic asthma
- Mild asthma
- Moderate asthma
- Occasional asthma
- Severe asthma
- Chemical-induced asthma
- Substance-induced asthma
- Intermittent asthma
- Seasonal Asthma
- Occupational Asthma
- Chronic obstructive airway disease with asthma
- Asthma with irreversible airway obstruction
- Untreated Asthma
- Persistent asthma
- Induced asthma
- Neutrophilic asthma
- Cortico-dependent asthma